FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Zg第一季度EBITDA超预期,但受法律和广告成本影响,预计第二季度盈利能力将下调。

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下: ZG第一季度营收为7.08亿美元,超出市场预期,同比增长18%,主要得益于抵押贷款(+56%)和租赁(+42%)业务的强劲增长,而核心住宅业务仅增长8%。尽管法律费用导致利润率下降160个基点,但经调整后的EBITDA仍达到1.82亿美元,高于市场预期的1.6839亿美元,这得益于强劲的成本控制和经调整后自由现金流同比增长44%。然而,由于前期广告支出较高以及新增2000万美元的法律费用,第二季度经调整后的EBITDA预期为1.5亿至1.65亿美元,远低于市场预期的1.9055亿美元。管理层重申了全年营收和利润率将实现两位数增长和提升的目标,这意味着下半年将出现显著复苏。我们认为,法律风险造成了重大的不确定性,持续的诉讼压力与内部流量指标的放缓(月均用户数同比下降3%)以及现金储备从第四季度的13亿美元减少至7.88亿美元同时出现。我们认为,公司在充满挑战的环境中,既要应对法律方面的阻力,又要保持增长势头,因此面临着执行风险。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661